Mass cytometry

Standard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Standard BioTools, Hyperion, Genomics, Security (finance), Terrorism, Vii, 600 (number), Supplement, Xi, Health, SBI, Appendix, EBITDA, SomaLogic, News, Form 10-Q, GAAP, Intellectual property, Doctor of Philosophy, Original equipment manufacturer, Research, COVID-19, Risk, Marketing, Annual report, Webcast, Form 10-K, Mass cytometry, Depreciation, Egholm, Standard, Total, Table, Investment, XV, Microfluidics, Hart–Scott–Rodino Antitrust Improvements Act, Failure, Reverse transcription polymerase chain reaction, Fine chemical, Bank, Mergers and acquisitions

As previously announced on October 4, 2023, the Company expects total revenue of $100 million to $105 million for the full year 2023.

Key Points: 
  • As previously announced on October 4, 2023, the Company expects total revenue of $100 million to $105 million for the full year 2023.
  • An explanation of these non-GAAP financial measures is also included below under the heading “Use of Non-GAAP Financial Information.
  • ET, to discuss third quarter 2023 financial results and operational progress as well as to provide additional color on its strategic actions.
  • Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis.

Standard BioTools Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 9, 2023
AACR, Table, Marketing, Supplement, Genomics, COVID-19, Audit committee, American Association for Cancer Research, Standard BioTools, GAAP, Research, Doctor of Philosophy, Investment, Annual report, Hyperion, SSF, SAN, Webcast, Growth, Security (finance), OEM, Health, Mass cytometry, News, Microfluidics, Pharmaceutical industry, Video game, Cryptocurrency, Communications satellite, Mobile phone, Management, Bank, Proteomics

ET

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the first quarter ended March 31, 2023.
  • The company expects to realize the financial benefits of the additional space reduction toward the end of 2023 and into 2024.
  • ET, to discuss first quarter 2023 financial results and operational progress as well as to provide additional color on its strategic actions.
  • Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis.

Standard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook

Retrieved on: 
Tuesday, February 14, 2023
Standard BioTools, Hyperion, Genomics, Microfluidics, Securities and Exchange Commission of Pakistan, Security (finance), Table, OEM, GAAP, Webcast, Proteomics, Health, Research, Human Genomics and Proteomics, Annual report, Marketing, FDA, Growth, SAN, AACR, Mass cytometry, Emergency Use Authorization, COVID, COVID-19, Depreciation, Doctor of Philosophy, American Association for Cancer Research, Video game, Computer data storage, Pharmaceutical industry, Cryptocurrency, Bank

ET

Key Points: 
  • ET
    SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today reported financial results for the fourth quarter and year ended December 31, 2022.
  • GAAP operating expenses were $32.3 million for the fourth quarter, a 16% decrease from the third quarter of 2022.
  • GAAP product and services margins are currently expected to increase to 52%–55% by the fourth quarter of 2023, representing an 1,100–1,400 basis point increase over the fourth quarter of 2022.
  • Non-GAAP product and services margins are expected to increase to 65%–68% by the fourth quarter of 2023, representing a 1,200–1,500 basis point increase over the fourth quarter of 2022.

Fluidigm Announces Preliminary Revenue Exceeding Guidance for the Fourth Quarter and Full Year 2021

Retrieved on: 
Tuesday, January 11, 2022
Biomarker, Research, Forward-looking statement, XT, Microfluidics, SAN, LinkedIn, Disclosure, Biotechnology, Private Securities Litigation Reform Act, Mass cytometry, FLDM, COVID-19, NASDAQ, Growth, CEO, Disease, Government, GLOBE, Regulation Fair Disclosure, Health, Regulation, U.S. Securities and Exchange Commission, Industry, CyTOF, United, Quality of life, Cancer, Twitter, Immunotherapy, Mission statement, Coronavirus, Social media, Annual report, Video game, Pharmaceutical industry, Facebook, Fluidigm

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM) today announced preliminary revenue for the fourth quarter and full year ended December 31, 2021, exceeding the company’s guidance for those periods.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM) today announced preliminary revenue for the fourth quarter and full year ended December 31, 2021, exceeding the companys guidance for those periods.
  • Fourth quarter 2021 total revenue of $38.0 to $38.3 million, exceeding the companys prior guidance range of $31$34 million.
  • Full year 2021 total revenue of $130.3 to $130.6 million, exceeding the companys prior guidance range of $123$127 million.
  • Base product and service revenue (excluding COVID-19 testing revenue) of $111.9 to $112.2 million, or a year-over-year growth of approximately 12%.

Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software

Retrieved on: 
Tuesday, October 12, 2021
Microfluidics, Marie Cassidy, Biotechnology, Drug development, Cancer, Research, Quality of life, United, Reading, Technology, Regulation Fair Disclosure, Twitter, AI, Life, CyTOF, Program, LinkedIn, Software, Artificial intelligence, U.S. Securities and Exchange Commission, Disclosure, Data mining, Solution, Disease, Government, NASDAQ, Regulation, SAN, Workflow, Precision medicine, Annual report, Deep learning, Coronavirus, Social media, Ecosystem, Private Securities Litigation Reform Act, Forward-looking statement, Mass cytometry, GLOBE, Industry, Health, Metadata, Immunotherapy, Security (finance), CEO, Biomarker, Pharmaceutical industry, Medical imaging

Visiopharm is a world leader in image analysis, with a mission to transform pathology through AI-based image analysis and workflow standardization, offering solutions for digital pathology.

Key Points: 
  • Visiopharm is a world leader in image analysis, with a mission to transform pathology through AI-based image analysis and workflow standardization, offering solutions for digital pathology.
  • New software developed in collaboration with Visiopharm will enable native reading of data files from the Hyperion Imaging System, which uses IMC technology, imported into Visiopharm analysis tools.
  • The new software will be launched at the 2021 Fluidigm IMC Summit on October 21.
  • This simplifies the workflow, enabling faster analysis of cellular phenotypes and their interrelationships within the spatial context of the tissue microenvironment.

Fluidigm Announces Co-Marketing Agreement with Ultivue for Biomarker Imaging Solutions for Precision Medicine

Retrieved on: 
Thursday, August 5, 2021
H&E stain, Efficiency, Research, Chief executive officer, U.S. Securities and Exchange Commission, Solution, Forward-looking statement, United, Industry, Life, Corporate development, Technology, Coronavirus, Data analysis, Annual report, Government, Private Securities Litigation Reform Act, Regulation, Security (finance), Mass cytometry, TIS, Health, Twitter, Microfluidics, Biomarker, GLOBE, Quality of life, Mass, Cancer, Regulation Fair Disclosure, SAN, Triage, Precision medicine, Social media, Immunotherapy, CyTOF, Drug development, Biotechnology, Disclosure, LinkedIn, Acquisition, Nasdaq, Disease, Pharmaceutical industry, Medical imaging, Risk management

Ultivue , a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique assays for use in multiplex immunofluorescence imaging and analysis.

Key Points: 
  • Ultivue , a leader in advancing precision medicine solutions by accelerating tissue biomarker discovery and validation, develops unique assays for use in multiplex immunofluorescence imaging and analysis.
  • For example, InSituPlex technology is well-suited to identify regions of interest that may require downstream, deep profiling with Imaging Mass Cytometry.
  • Ultivue is at the forefront of innovation to provide unique biological insights for our customers, said Mark Rees, Vice President of Corporate Development for Ultivue.
  • Through Fluidigm Therapeutic Insights Services, we will offer our customers access to our technology as well as that of Ultivue, providing optimum imaging solutions for biomarker discovery and drug development.

Imaging Mass Cytometry Utilized by Global Consortium Focused on New Precision Medicine Approaches for Treatment of Rheumatoid Arthritis

Retrieved on: 
Monday, May 24, 2021
Branches of biology, Medical specialties, Joints, Medicine, Rheumatology, Cell biology, Clinical pathology, Laboratory techniques, Mass cytometry, Synovial fluid, Hyperion, IMC

RA, an autoimmune inflammatory disorder characterized by synovial joint inflammation, affects ~0.5 to 1 percent of the global population.

Key Points: 
  • RA, an autoimmune inflammatory disorder characterized by synovial joint inflammation, affects ~0.5 to 1 percent of the global population.
  • To assist consortium researchers, Fluidigm is providing training, support, and equipment to perform Imaging Mass Cytometry (IMC) studies utilizing a Hyperion Imaging System at the University of Eastern Piedmont in Novara, Italy.
  • Fluidigm, theFluidigmlogo, Advanta, CyTOF, Hyperion, Imaging Mass Cytometry, and IMC are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.
  • FLAMIN-GOs mission is to develop a personalized next-generation synovia-on-chip that by effectively mimicking the complexity of a rheumatoid arthritic joint, will permit patient-specific clinical trials-on-chip.

Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Biology, Cell biology, Flow cytometry, Clinical pathology, Laboratory techniques, Mass spectrometry, XC2, Mass cytometry, CyTOF, Cytomics, Cytometry Part A

These analyses demonstrated that mass cytometry-based phenotypic footprints captured distinct features not detected using typical genetic and genomic evaluations.

Key Points: 
  • These analyses demonstrated that mass cytometry-based phenotypic footprints captured distinct features not detected using typical genetic and genomic evaluations.
  • \xe2\x80\x9cIntegrating phenotypic data with molecular and drug response data from the same xenografts, we found that phenotypic heterogeneity at the cellular level is a critical determinant of drug response.
  • This was really key to expanding our understanding of how specific cell phenotypes are spatially distributed and their clinical relevance.
  • For more information, visit fluidigm.com .\nFluidigm, the\xc2\xa0Fluidigm\xc2\xa0logo, Advanta, CyTOF, Imaging Mass Cytometry, and IMC are trademarks and/or registered trademarks of\xc2\xa0Fluidigm Corporation\xc2\xa0in\xc2\xa0the United States\xc2\xa0and/or other countries.

At 9% CAGR, Flow Cytometry Market is Anticipated to reach USD 10.57 Billion by 2026 | Analysis by Current Trends, Statistics Growth, Covid-19 Impact | Brandessence Market Research

Retrieved on: 
Wednesday, April 21, 2021
Branches of biology, Biology, Cell biology, Flow cytometry, Laboratory techniques, Clinical pathology, Blood tests, Cytometry, Mass cytometry, CyTOF, Flow cytometry bioinformatics

As this pandemic affected all the sectors of the market, so it affected global Flow Cytometry Market as well.

Key Points: 
  • As this pandemic affected all the sectors of the market, so it affected global Flow Cytometry Market as well.
  • This method allows the quantitative and qualitative analysis of cell populations from fresh unfixed tissue or body fluid.
  • Also this technology pairs with beckman coulter's CytoFLEX LX 21-color flow cytometer for data analysis needs of clinical research scientist.
  • Hence increasing use of Flow cytometry in diagnosis of cancer or immunodeficient diseases flow cytometry is used.

At 9% CAGR, Flow Cytometry Market is Anticipated to reach USD 10.57 Billion by 2026 | Analysis by Current Trends, Statistics Growth, Covid-19 Impact | Brandessence Market Research

Retrieved on: 
Wednesday, April 21, 2021
Branches of biology, Biology, Cell biology, Flow cytometry, Laboratory techniques, Clinical pathology, Blood tests, Cytometry, Mass cytometry, CyTOF, Flow cytometry bioinformatics

As this pandemic affected all the sectors of the market, so it affected global Flow Cytometry Market as well.

Key Points: 
  • As this pandemic affected all the sectors of the market, so it affected global Flow Cytometry Market as well.
  • This method allows the quantitative and qualitative analysis of cell populations from fresh unfixed tissue or body fluid.
  • Also this technology pairs with beckman coulter's CytoFLEX LX 21-color flow cytometer for data analysis needs of clinical research scientist.
  • Hence increasing use of Flow cytometry in diagnosis of cancer or immunodeficient diseases flow cytometry is used.